RG
RGBP.US Regen BioPharma Inc
- Market cap
- USD 203K
- P/E
- -
- P/B
- 251.28x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is RGBP.US undervalued?
Graham numberThe Graham number of Regen BioPharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Regen BioPharma Inc fundamental analysis
No fundamental analysis for Regen BioPharma Inc yet.
Regen BioPharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Regen BioPharma Inc
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from autologous stromal vascular fraction from adipose tissue; dCellVax, an autologous …
Full company profileRegen BioPharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Regen BioPharma Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 100K | 110K | 100K | 110K | 110K | 171K | 236K | 237K | 237K | 237K | 236K |
| Gross Profit | 100K | 110K | 100K | - | - | 146K | 186K | 237K | 159K | 237K | 236K |
| Operating Income | -2.96M | -2.51M | -1.43M | -757K | -209K | -201K | -340K | -687K | -418K | -339K | -908K |
| EBITDA | -3.35M | -4.79M | -1.85M | -921K | 4.36M | -6.35M | 2.77M | 1.22M | -418K | -1.01M | -873K |
| Net Income | -3.41M | -5.84M | -4.72M | -2.62M | 2.73M | -6.77M | 2.23M | 1.02M | -867K | -1.27M | -818K |
| EPS | -40 | -62 | -47 | 0.00 | 0.00 | -3.37 | 0.71 | 0.14 | -0.10 | -0.05 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 319K | 944K | 209K | 99.1K | 123K | 1.21M | 559K | 354K | 178K | 275K | 288K |
| Total Liabilities | 906K | 6.20M | 9.33M | 11.0M | 7.46M | 14.7M | 8.60M | 5.46M | 5.37M | 6.56M | 6.17M |
| Shareholders' Equity | -587K | -5.25M | -9.12M | -10.9M | -7.33M | -13.5M | -8.04M | -5.10M | -5.19M | -6.28M | -5.88M |
| Cash & Short-term Investments | 24.8K | 270K | 8.02K | 7.86K | 0.00 | 727K | 51.2K | 121K | 716.00 | 716.00 | 239.00 |
| Total Debt | 260K | 693K | 1.43M | - | - | 3.58M | 1.27M | 756K | 815K | 794K | 925K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.67M | -1.89M | -1.58M | -482K | 18.6K | -1.13M | -607K | -174K | -693K | -384K | -380K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 0.00 | 0.00 | 13.33 |
| Free Cash Flow | -1.67M | -1.89M | -1.58M | -482K | 18.6K | -1.13M | -607K | -174K | -693K | -384K | -380K |
| Ratios | |||||||||||
| ROA | -1,069.0% | -618.4% | -2,255.8% | -2,647.3% | 2,217.4% | -558.1% | 398.4% | 289.6% | -488.3% | -464.1% | -284.5% |
| Net Profit Margin | -3,414.0% | -5,308.2% | -4,715.0% | -2,384.7% | 2,483.2% | -3,951.7% | 945.6% | 432.9% | -366.6% | -538.8% | -346.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Regen BioPharma Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 5.74K | 0.06 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Nov 4, 2024.
Who owns Regen BioPharma Inc
- Insiders 2.50%
- Institutions 0.00%
- Public & others 97.50%
- Shares outstanding 2.03B
- Free float 1.62B
Regen BioPharma Inc company profile
- Company name
- Regen BioPharma Inc
- Ticker
- RGBP.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- September
- Address
- 8697 La Mesa Boulevard, La Mesa, CA, United States, 91942
- Phone
- 619 722 5505
- Website
- regenbiopharmainc.com
About Regen BioPharma Inc
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from autologous stromal vascular fraction from adipose tissue; dCellVax, an autologous dendritic cell treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax, which is treated with siRNA to inhibit NR2F6, with the cells re-infused into the patient; DiffronC, which uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuraCAR, comprising CAR-T cells treated with an shRNA targeting the gene NR2F6. Regen BioPharma was incorporated in 2012 and is based in La Mesa, California.
Regen BioPharma Inc management
1- Dr. David Raymond Koos DBA, Ph.D.Chairman, CEO, President, Acting CFO, Secretary & Treasurer · born 1961